Dual immunotherapy combination of Opdivo plus Yervoy demonstrated improved survival benefit compared to lenvatinib or sorafenib in this patient population
Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson’s disease
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use
Open a printable version of this pageEmail the URL of this page to a friend
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
This new medication eliminates the need for cold storage, making it more accessible and affordable for SCD patients across India
AbCellera will receive an upfront payment and is eligible to receive additional milestone payments
Subscribe To Our Newsletter & Stay Updated
